**Survivorship – Adult Cardiovascular Screening**

**PRESENTATION**

At initial survivorship visit:
- Assess access to primary health care
- Blood pressure check
- Baseline lipid panel and as clinically indicated
- Baseline electrocardiogram (ECG)
- Assess cardiovascular risk factors
- Calculate patient’s ASCVD risk
- Lifestyle risk assessment

**CARDIOVASCULAR RISK FACTORS**

- High-dose anthracycline (doxorubicin ≥ 250 mg/m²)
- Lower dose anthracycline in combination with radiation to the heart or mediastinum and/or trastuzumab
- Patient history to include ≥ 2 risk factors

**CARDIOVASCULAR SCREENING**

(To start from the completion of treatment)

- ECG
  - Annually for ages ≥ 60 years at the time of treatment
  - Every 5 years for ages < 60 years at the time of treatment
- ECHO at 6 months, 1 year, 3 years, 5 years, then every 5 years thereafter
- Age < 60 years old at the time of treatment
  - ECG every 5 years
  - ECHO at 6 months, 1 year, then every 5 years thereafter
- Age ≥ 60 years old at the time of treatment
  - ECG annually
  - ECHO at 6 months, 1 year, 3 years, 5 years, then every 5 years thereafter

Radiation therapy

Low-dose anthracycline treatment without radiation or trastuzumab and no other risk factors

Regardless of age at the time of the treatment:
- Heart or mediastinum in the radiation field
  - ECHO every 5 years
  - Stress test or coronary CTA at 10 years then every 5 years thereafter
- Neck
  - Baseline carotid duplex
    - For normal results, obtain every 5 years thereafter
    - For abnormal results, obtain annually if < 50% stenosis and every 6 months if > 50% stenosis
- Pelvis
  - Ankle-brachial index with arterial waveforms at 10 years then every 5 years thereafter
  - Renal duplex if hypertension or worsening renal function

ASCVD = atherosclerotic cardiovascular disease
CTA = computed tomography angiogram
LBBB = left bundle branch block
LVEF = left ventricular ejection fraction
RBBB = right bundle branch block

1 Recommend patient to follow-up with their primary care provider for management of abnormal findings. If patient does not have one established, consider referral to Cardiology or General Internal Medicine (GIM) for temporary management until patient establishes care with a local provider.

GIM criteria for referral:
- For blood pressure, SBP > 140 mmHg or DBP > 90-120 mmHg
- For heart rate between 100-120 bpm
- For lipid panel, LDL 100-189 mg/dL or triglyceride > 300 mg/dL.

2 Blood pressure goal < 130/80 mmHg

3 Low-density lipoprotein-cholesterol (LDL-C) goal < 100 mg/dL. If radiation to the heart, LDL-C goal < 70 mg/dL. Consider Cardiology referral for established coronary calcifications or plaque, or carotid atherosclerosis.

4 Referral to Cardiology if results show evidence of prior infarction, ischemia, LBBB, RBBB, atrial fibrillation/flutter, or abnormal ECG (depending on provider’s comfort level)

5 For risk refer to ASCVD Risk Estimator Plus

6 See Physical Activity, Nutrition, and Tobacco Cessation Treatment algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

7 Risk factors during or after completion of treatment: smoking, hypertension, diabetes, dyslipidemia, or obesity

8 Referral to Cardiology if results show LVEF < 50%, ≥ moderate valvular regurgitation, any degree of stenosis, or constriction. Consider referral to Cardiology if LVEF < 55%, particularly those whose LVEF has been declining or is < 53%

9 Consider referral to Cardiology if results show plaque or stenosis

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.
SUGGESTED READINGS

Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., . . . Lenihan, D. (2017). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology, 35*(8), 893-911. https://doi.org/10.1200/JCO.2016.70.5400

Curigliano, G., Lenihan, D., Bradly, M., Ganatra, S., Barac, A., Blaes, A., . . . Jordan, K. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: EMSO consensus recommendations. *Annals of Oncology, 31*(2), 171-190. https://doi.org/10.1016/j.annonc.2019.10.023

Hoppe, R. T., Ai, W. Z., Aoun, P., Benitez, C. M., Blum, K. A., Forero, A., . . . Kenkre, V. P. (2017). Hodgkin lymphoma (Version 1.2017). *Journal of the National Comprehensive Cancer Network, 15*(5), 608-638. https://doi.org/10.6004/jnccn.2017.0064

Koutroumpakis, E., Palaskas, N. L., Lin, S. H., Abe, J.-I., Liao, Z., Banchs, J., . . . Yusuf, S. W. (2020). Modern radiotherapy and risk of cardiotoxicity. *Chemotherapy, 65*(3-4), 65-76. https://doi.org/10.1159/000510573

Lancellotti, P., Nkomo, V. T., Badano, L. P., Bergler, J., Bogaert, J., Davin, L., . . . Society of Cardiovascular Computed Tomography. (2013). Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *Journal of the American Society of Echocardiography, 26*(9), 1013-1032. https://doi.org/10.1016/j.echo.2013.07.005

Lyon, A. R., Lopez-Fernandez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., . . . ESC Scientific Document Group. (2022). 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *European Heart Journal, 43*(41), 4229-4361. https://doi.org/10.1093/eurheartj/ehac244

Lyon, A. R., Lopez-Fernandez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., . . . ESC Scientific Document Group. (2022). Erratum to: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *European Heart Journal, 44*(18), 1621. https://doi.org/10.1093/eurheartj/ehad196
DeVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Cardiovascular Survivorship workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads
Ihab Hamzeh, MD (Cardiology)

Workgroup Members
Sairah Ahmed, MD (Lymphoma-Myeloma)
Jennifer Alpard, PA-C (Head & Neck Surgery)
Carlos H. Barcenas, MD, MSc (Breast Medical Oncology)
Wendy Garcia, BS*
Katherine Gilmore, MPH (Cancer Survivorship)
Thoa Kazantsev, MSN, RN, OCN*
Haleigh Mistry, MS, PA-C (Lymphoma-Myeloma)
Ellen Mullen, PhD, MSN, RN (Lymphoma-Myeloma)
William Osai, MSN, RN (Genitourinary Medical Oncology)
Chelsea Pinnix, MD, PhD (Radiation Oncology)
Justine Robinson, MPAS, PA-C (Head & Neck Surgery)
Alma Rodriguez, MD (Lymphoma-Myeloma)
Shawn Terry, MSPA (Head & Neck Surgery)
Whitney Thomann, MS, ACSM-CEP, ACSM-CET (Cancer Survivorship)
Angela Yarbrough, DNP, APRN, FNP-BC (Pediatrics)

* Clinical Effectiveness Development Team